IRF1 and Familial prostate cancer: cf-WES also revealed likely oncogenic alterations not covered by the cf-IMPACT assay design including a likely oncogenic frameshift deletion in the tumor suppressor IRF1 [36] in a prostate cancer patient, and in a urothelial cancer patient a likely oncogenic frameshift deletion in EP400, which encodes a component of the NuA4 histone acetyltransferase complex that positively regulates transcription [37].